SynthesisFrontiers in pharmacology2026
The impact of ustekinumab and tumor necrosis factor antagonists on extraintestinal manifestations of Crohn's disease: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Extraintestinal manifestations (EIMs) are commonly observed in patients with Crohn's disease (CD). Although Tumor Necrosis Factor (TNF) antagonists are commonly recommended for the management of several EIMs, their efficacy remains limited. Ustekinumab (UST), an alternative option after TNF antagonists failure, has shown potential efficacy for various EIMs. However, evidence regarding its effectiveness remains inconsistent. This study aimed to evaluate the efficacy and safety of UST and TNF antagonists for CD-related EIMs through a systematic review and meta-analysis. Methods: PubMed, Embase, and Cochrane Library were searched on 2 August 2025, to identify phase II and III randomized controlled trials (RCTs) evaluating UST or TNF antagonists in adults aged ≥18 years with moderate-to-severe active CD. The primary outcomes were EIMs and EIM-related symptoms. Two investigators, adhering to the PRISMA guidelines, independently screened the literature and extracted data. The risk of bias was assessed using the Cochrane Risk-of-Bias Tool 2.0. Random-effects and fixed-effect models were used to estimate pooled treatment effects. Results were presented using risk ratios (RRs), incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Results: A total of 23 RCTs, involving 7,810 patients, were included, with EIMs such as fatigue, joint pain, and skin manifestations being considered. The meta-analysis revealed that UST significantly reduced the risk of fatigue in CD patients (IRR 0.53, 95% CI 0.33-0.84, P = 0.008). During maintenance therapy, UST treatment was significantly associated with a reduction in the risk of arthritis/arthralgia (IRR 0.56, 95% CI 0.36-0.86, P = 0.008). Weekly adalimumab (ADA) treatment was significantly associated with an increased risk of fatigue (IRR 2.79, 95% CI 1.12-6.94, P = 0.028). Conclusion: UST showed potential advantages in the management of fatigue and arthritis/arthralgia. ADA and infliximab (IFX) were not associated with statistically significant benefits for most analyzed EIM outcomes. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251111502, identifier CRD420251111502.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.